×
About 18,495 results

ALLMedicine™ Hodgkin Lymphoma Center

Research & Reviews  6,059 results

Impact of Frailty on Hospital Outcomes Among Patients with Lymphoid Malignancies Receiv...
https://doi.org/10.1016/j.clml.2021.12.017
Clinical Lymphoma, Myeloma & Leukemia; Rubens M, Cristian A et. al.

Jan 15th, 2022 - Frailty could affect outcomes of autologous hematopoietic stem cell transplantation (aHSCT). This study sought to examine the effects of frailty on hospital outcomes among patients with non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and multip...

Radiotherapy planning of lymphomas: role of metabolic imaging with PET/CT.
https://doi.org/10.1007/s12149-021-01703-7
Annals of Nuclear Medicine; McKay MJ, Taubman KL et. al.

Jan 15th, 2022 - Accurate target delineation is an absolute requirement for modern radiotherapy planning. Historically, structural imaging modalities have been used for this purpose, but there is a considerable role for functional imaging with PET/CT to contribute...

EBV+ tumors exploit tumor cell-intrinsic and -extrinsic mechanisms to produce regulator...
https://doi.org/10.1371/journal.ppat.1010200
PLoS Pathogens; Jorapur A, Marshall LA et. al.

Jan 14th, 2022 - The Epstein-Barr Virus (EBV) is involved in the etiology of multiple hematologic and epithelial human cancers. EBV+ tumors employ multiple immune escape mechanisms, including the recruitment of immunosuppressive regulatory T cells (Treg). Here, we...

The follicular lymphoma epigenome regulates its microenvironment.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753841
Journal of Experimental & Clinical Cancer Research : CR; Amin R, Braza MS

Jan 14th, 2022 - Follicular lymphoma (FL) is a B-cell non-Hodgkin lymphoma of germinal center (GC) origin with a distinctive tumor microenvironment (TME) and a unique spectrum of mutations. Despite the important therapeutic advances, FL is still incurable. During ...

Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)
https://clinicaltrials.gov/ct2/show/NCT04456023

Jan 12th, 2022 - Disease assessments will be performed at screening, after bridging, 1, 3, 6, 9 and 12 months after tisagenlecleucel infusion, and every 6 months in the second year, and annually up to 60 months after infusion. Efficacy will be assessed until progr...

see more →

Guidelines  17 results

UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic La...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894347
British Journal of Haematology; Turton P, El-Sharkawi D et. al.

Nov 23rd, 2020 - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast sy...

Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, A...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723685
Journal of Clinical Oncology : Official Journal of the Am... Mulder RL, Hudson MM et. al.

Oct 21st, 2020 - As new evidence is available, the International Late Effects of Childhood Cancer Guideline Harmonization Group has updated breast cancer surveillance recommendations for female survivors of childhood, adolescent, and young adult cancer. We used ev...

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Gu...
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow...
https://doi.org/10.1093/annonc/mdy080
Annals of Oncology : Official Journal of the European Soc... Eichenauer DA, Aleman BMP et. al.

Oct 1st, 2018 - Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2018|Eichenauer DA,Aleman BMP,André M,Federico M,Hutchings M,|diagnosis,epidemiology,therapy,standards,

Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in ...
https://doi.org/10.6004/jnccn.2018.0066
Journal of the National Comprehensive Cancer Network : JN... Reid E, Suneja G et. al.

Aug 14th, 2018 - People living with HIV (PLWH) are diagnosed with cancer at an increased rate over the general population and generally have a higher mortality due to delayed diagnoses, advanced cancer stage, comorbidities, immunosuppression, and cancer treatment ...

see more →

Drugs  62 results see all →

Clinicaltrials.gov  285 results

Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)
https://clinicaltrials.gov/ct2/show/NCT04456023

Jan 12th, 2022 - Disease assessments will be performed at screening, after bridging, 1, 3, 6, 9 and 12 months after tisagenlecleucel infusion, and every 6 months in the second year, and annually up to 60 months after infusion. Efficacy will be assessed until progr...

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients
https://clinicaltrials.gov/ct2/show/NCT03610724

Jan 12th, 2022 - This study is part of an agreed Pediatric Investigation Plan (PIP). The single-arm study design includes r/r B-cell NHL subject population with poor prognosis, lack of approved effective therapies in this setting. Subject population will include a...

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Ped...
https://clinicaltrials.gov/ct2/show/NCT03526250

Jan 12th, 2022 - PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with palbociclib with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymph...

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03907488

Jan 12th, 2022 - PRIMARY OBJECTIVE: I. To compare the progression-free survival (PFS) in patients with newly diagnosed advanced stage classical Hodgkin lymphoma randomized to N-AVD (nivolumab, doxorubicin hydrochloride [doxorubicin], vinblastine sulfate [vinblasti...

Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04775680

Jan 12th, 2022 - This is a Multicenter, Open-Label, Phase Ib/II Study of ADG106 in Combination with PD-1 Antibody in Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. The primary objective of Phase Ib: To evaluate the maximum tolerated dosage (MT...

see more →

News  970 results

Rapid Readout: Pirtobrutinib, A Highly Selective, Noncovalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study
https://www.onclive.com/view/pirtobrutinib-a-highly-selective-non-covalent-reversible-btk-inhibitor-in-previously-treated-cll-sll-updated-results-from-the-phase-1-2-bruin-study

Jan 14th, 2022 - Anthony Mato, MD, discusses data from the following presentation: Updated results from the phase 1/2 BRUIN study of the noncovalent BTK inhibitor (BTKi) pirtobrutinib in patients with previously treated chronic lymphocytic leukemia/small lymphocy...

FDA Grants RMAT/Fast Track Designations to C-CAR039 for Relapsed/Refractory DLBCL
https://www.onclive.com/view/fda-grants-rmat-fast-track-designations-to-c-car039-for-relapsed-refractory-dlbcl

Jan 12th, 2022 - The FDA has granted a regenerative medicine advanced therapy (RMAT) designation and a fast track designation to C-CAR039 for use as a potential therapeutic option in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).1 A n...

Non-Hodgkin Lymphoma Updates From ASH 2021
https://www.mdedge.com/fedprac/article/250343/conference-recap/non-hodgkin-lymphoma-updates-ash-2021
Brad Kahl, MD

Jan 6th, 2022 - Brad Kahl, MD, shares results from non-Hodgkin lymphoma clinical trials that were presented at the 2021 American Society of Hematology (ASH) Annual Meeting. Dr Kahl looks first at a frontline study examining a new combination therapy.

First-in-Class ADC Expands Portfolio of Precision Therapies in Bladder Cancer
https://www.onclive.com/view/firstinclass-adc-expands-portfolio-of-precision-therapies-in-bladder-cancer

Jan 3rd, 2022 - Bradley A. McGregor, MD The bladder cancer armamentarium gained a powerful agent in December 2019 with the approval of enfortumab vedotin-ejfv (Padcev), a Nectin-4—directed antibody-drug conjugate (ADC). The agency granted accelerated approval to...

Dr. Riedell on the Effects of Time to Relapse on Outcomes in MCL
https://www.onclive.com/view/dr-riedell-on-the-effects-of-time-to-relapse-on-outcomes-in-mcl

Dec 21st, 2021 - Peter Riedell, MD, assistant professor of medicine, University of Chicago Medicine, discusses the effects of time to relapse on outcomes in mantle cell lymphoma (MCL). Findings from an analysis examining the effect of time to relapse on overall...

see more →

Patient Education  5 results see all →